BRONJBisphosphonate-Related Osteonecrosis of the Jaw (also seen as BROJ)
References in periodicals archive ?
4 Although exact etiology of BRONJ is still unknown, the pathway of it is very clear such as prescription of biphosphonates, long term usage of the drug and history of dental trauma or oral surgery.
Regarding this pathway, it is very important to evaluate the patients dental situation and oral hygiene before and during the bisphosphonate therapy to prevent BRONJ.
Do you follow literature especially for BRONJ and if yes from which journal?
Per the 2009 update to the AAOMS guidelines, the goals of treatment for patients with BRONJ are preservation of quality of life while supporting the ongoing treatment.
Treatment for Stage 1 and 2 BRONJ is typically medical.
Patients are often placed on BPs for metastatic disease, which, when affecting the mouth, can present with symptoms similar to BRONJ.
While the majority of patients on intravenous (IV) and oral bisphosphonates will not develop BRONJ, it is important to understand the risk factors for the disease.
The AAOMS Staging and Treatment Strategies For BPs Associated BRONJ (16)
7 cases per 100000 person years exposure) of developing BRONJ
Patients may be considered to have BRONJ if all of the following three characteristics are present:
It is important to understand that patients at risk for BRONJ or with established BRONJ can also present with other common clinical conditions that should not be confused as BRONJ.
In the vast majority of BRONJ cases reported to date, recent dentoalveolar trauma was the most prevalent and consistent risk factor.